A research team has conducted a study exploring the role of the mannose pathway in regulating cell fate decisions in low glucose environments. Their work may hold potential for novel therapeutic ...

Rapid developments in gene-modified cell therapies, especially CAR T-cell therapies, has increased demand for fast and reliable analytics methods for research, in-process development, and ...

RASolute 302 Phase 3 catalyst, cash runway, and valuation risks for daraxonrasib. Read more macro analysis here.

Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on ...

OmniAb, Inc. ( OABI) Q4 2025 Earnings Call March 4, 2026 4:30 PM EST Good afternoon, and welcome to OmniAb, Inc.'s First -- Fourth Quarter 2025 Financial Results and Business Update Conference Call.

Welcome to our second issue of 2026 of The Health Record -- our healthcare law insights e-newsletter. In this edition, we look ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Zahra Mahmoudjafari explains how cell and gene therapy programs succeed with strong infrastructure, pharmacy leadership, ...

Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...

Outpatient migration, bispecific adoption, and non-oncology trial expansion are increasing capacity pressure, making flexible ...

Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, tod ...